Fibromyalgia genetic risk factors identified
Analysis based on 9 articles · First reported Jul 27, 2026 · Last updated Jul 28, 2026
The findings may spur investment in fibromyalgia drug development, particularly targeting GPR52 and HTT pathways. However, no immediate diagnostic or therapeutic changes are expected, limiting short-term market impact.
A landmark study published in Nature Medicine on July 28, 2026, identified 26 genetic risk variants for fibromyalgia syndrome, confirming a biological basis for the condition. The international team, co-led by researchers from King s College London, Lunenfeld-Tanenbaum Research Institute, Fred Hutchinson Cancer Center, and University of Helsinki, analyzed genetic data from over 2.5 million adults, including 55,000 fibromyalgia patients. The strongest variant was in the HTT gene, linked to Huntington's disease, and another pointed to GPR52, a drug target for Huntington's. The study found genetic overlap with low back pain, irritable bowel syndrome, and PTSD, suggesting shared nervous system mechanisms. The researchers founded the Chronic Pain Genomics Consortium to investigate other chronic pain syndromes.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard